Page last updated: 2024-11-05

8-aminoquinoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

8-aminoquinoline is a heterocyclic organic compound used in the synthesis of pharmaceuticals and other fine chemicals. It is a key intermediate in the production of chloroquine, a widely used antimalarial drug. 8-aminoquinoline is also used in the synthesis of other antimalarial drugs, such as primaquine, and has been explored for its potential in treating other parasitic infections. The compound is known for its ability to inhibit the growth of Plasmodium falciparum, the parasite responsible for malaria. Research on 8-aminoquinoline continues to explore its potential in treating infectious diseases and other medical conditions.'

Cross-References

ID SourceID
PubMed CID11359
CHEMBL ID99932
SCHEMBL ID159694
MeSH IDM0214928

Synonyms (65)

Synonym
BIDD:GT0148
nsc 7933
wr 6920
einecs 209-427-9
8-quinolylamine
brn 0114474
ccris 1683
nc 066
CHEMBL99932
5-22-10-00316 (beilstein handbook reference)
u34eav21tg ,
unii-u34eav21tg
BB 0221197
8-aminoquinoline ,
nsc7933
8-quinolinamine
quinoline, 8-amino-
nsc-7933
578-66-5
SDCCGMLS-0065843.P001
AS-232 ,
quinolin-8-amine
inchi=1/c9h8n2/c10-8-5-1-3-7-4-2-6-11-9(7)8/h1-6h,10h2
wrevvzmunpapov-uhfffaoysa-
8-aminoquinoline, 98%
STK344576
quinolin-8-ylamine
AC-907/25014399
A0419
AKOS000108492
MLS-0065843.0001
A831646
NCGC00184185-02
NCGC00184185-01
EN300-10405
BP-13199
FT-0621492
q8a ,
AM20050982
AB00375631-02
aminoquinoline, 8-
8-quinolinylamine
aminoquinoline [vandf]
8-aminoquinoline [vandf]
SCHEMBL159694
PS-5383
8-amino-quinoline
8-amino quinoline
quinolin-8-yl-amine
DTXSID4060369
AC-10209
J-200081
W-206848
bdbm32144
cid_11359
us9394254, 18
mfcd00006809
CS-W007317
F2190-0534
SY012863
Q4644259
8-quinolinamine;8-quinolylamine
BCP32569
SB40763
HY-W007317

Research Excerpts

Toxicity

ExcerptReferenceRelevance
") challenge with a 2 x LD50 dose (5."( Comparison of methemoglobin formers in protection against the toxic effects of cyanide.
Baskin, SI; Fricke, RF; Scharf, BA, 1992
)
0.28
" On-therapy adverse events were observed for sitamaquine in 4 (10%) of 41 patients and for AmB in 17 (85%) of 20 patients."( Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India.
Al-Banna, M; Buckley, R; Dixon, SA; Miller, AK; Mohamed, K; Sinha, PK; Sundar, S, 2011
)
0.37
" The objective of this systematic review was to assess the risk of adverse effects in people with G6PD deficiency given primaquine or other 8-aminoquinoline (8AQ) as a single dose or short course (less than 7 days)."( Safety of 8-aminoquinolines given to people with G6PD deficiency: protocol for systematic review of prospective studies.
Clarke, A; Garner, P; Gelband, H; Graves, P; Saunders, R; Sinclair, D; Uthman, OA, 2014
)
1.01

Pharmacokinetics

ExcerptReferenceRelevance
"hr/mL, maximum plasma concentration (C(max)) = 401-570 ng/mL, apparent terminal half-life (t(1/2)) = 18."( Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India.
Al-Banna, M; Buckley, R; Dixon, SA; Miller, AK; Mohamed, K; Sinha, PK; Sundar, S, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" However, primaquine exhibits low oral bioavailability due to oxidative deamination of its aliphatic chain."( Peptidomimetic and organometallic derivatives of primaquine active against Leishmania infantum.
Gomes, MS; Gomes, P; Matos, J; Moreira, R; Tomás, A; Vale, N; Vale-Costa, S, 2012
)
0.38
" The clinical application is envisioned as a single subcutaneous administration, and the lead tafenoquine polymer also showed excellent bioavailability and liver-to-blood ratios exceeding the IV administered polymer."( Liver-targeted polymeric prodrugs of 8-aminoquinolines for malaria radical cure.
Burke, PA; Chavas, TEJ; Flaherty, SM; Ho, DK; Huber, HE; Jackson, C; LeGuyader, CLM; Li, Q; Lin, H; Maktabi, M; Pottenger, A; Pybus, B; Rochford, R; Roy, D; Srinivasan, S; Stayton, PS; Strauch, P; Vlaskin, V; Wesche, D; Zhang, J, 2021
)
0.89

Dosage Studied

ExcerptRelevanceReference
" WR6026 demonstrated the unusual clinical features of lack of increased efficacy against Brazilian kala-azar with increased dosing above 2 mg/kg/day and toxicity that was not present in previous investigations."( Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi.
Berman, J; Brewer, T; Carvalho, SF; Dietze, R; Grogl, M; Milhous, W; Sanchez, J; Schuster, B; Valli, LC, 2001
)
0.57
" This was an open-label, dose-increasing study to determine the dose-response and safety profile for sitamaquine in Kenyan patients with VL caused by Leishmania donovani."( A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya.
Albert, MJ; Felton, JM; Horton, J; Kinoti, D; Kirigi, G; Lodenyo, H; Mbui, J; Rashid, JR; Sabin, AJ; Wasunna, MK, 2005
)
0.33
"This randomized, open label, multicenter study assessed the dose-response and safety profile for oral sitamaquine in 120 Indian subjects with visceral leishmaniasis (VL)."( A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.
Felton, JM; Horton, J; Jha, TK; Sabin, AJ; Sundar, S; Thakur, CP, 2005
)
0.33
" The (-)-enantiomer NPC1161B was found to be more active (by severalfold, depending on the dosing regimen) than the (+)-enantiomer NPC1161A in all of these murine models."( Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate.
Ager, AL; Bartlett, MS; Croft, SL; Khan, IA; McChesney, JD; Nanayakkara, NP; Walker, LA; Yardley, V, 2008
)
0.58
" Analysis of whole-body mouse thin tissue sections from animals dosed with propranolol, adhered to an adhesive tape substrate, provided semiquantitative information for propranolol and its hydroxyproranolol glucuronide metabolite within specific organs of the tissue."( Application of a liquid extraction based sealing surface sampling probe for mass spectrometric analysis of dried blood spots and mouse whole-body thin tissue sections.
Kertesz, V; Van Berkel, GJ, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency3.70090.000811.382244.6684AID686978; AID686979
67.9K proteinVaccinia virusPotency2.81840.00018.4406100.0000AID720579
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
90-kda heat shock protein beta HSP90 beta, partialHomo sapiens (human)IC50 (µMol)50.00000.17369.803229.2701AID712
heat shock protein HSP 90-alpha isoform 2Homo sapiens (human)IC50 (µMol)50.00000.17369.803229.2701AID712
26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)IC50 (µMol)100.00000.00701.09812.5000AID1480589
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
double-strand break repair via homologous recombination26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
double-strand break repair via nonhomologous end joining26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
response to ethanol26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
regulation of proteasomal protein catabolic process26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
protein K63-linked deubiquitination26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
protein deubiquitination26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
superoxide anion generationNeutrophil cytosol factor 1Homo sapiens (human)
protein targeting to membraneNeutrophil cytosol factor 1Homo sapiens (human)
superoxide metabolic processNeutrophil cytosol factor 1Homo sapiens (human)
cellular defense responseNeutrophil cytosol factor 1Homo sapiens (human)
cellular response to reactive oxygen speciesNeutrophil cytosol factor 1Homo sapiens (human)
superoxide anion generationNeutrophil cytosol factor 1Homo sapiens (human)
innate immune responseNeutrophil cytosol factor 1Homo sapiens (human)
respiratory burstNeutrophil cytosol factor 1Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityNeutrophil cytosol factor 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionNeutrophil cytosol factor 1Homo sapiens (human)
positive regulation of JNK cascadeNeutrophil cytosol factor 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNeutrophil cytosol factor 1Homo sapiens (human)
regulation of respiratory burst involved in inflammatory responseNeutrophil cytosol factor 1Homo sapiens (human)
cellular response to cadmium ionNeutrophil cytosol factor 1Homo sapiens (human)
cellular response to glucose stimulusNeutrophil cytosol factor 1Homo sapiens (human)
cellular response to testosterone stimulusNeutrophil cytosol factor 1Homo sapiens (human)
positive regulation of p38MAPK cascadeNeutrophil cytosol factor 1Homo sapiens (human)
reactive oxygen species biosynthetic processNeutrophil cytosol factor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
protein binding26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
metallopeptidase activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
metal ion binding26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
endopeptidase activator activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
K63-linked deubiquitinase activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome binding26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
metal-dependent deubiquitinase activity26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
protein bindingNeutrophil cytosol factor 1Homo sapiens (human)
electron transfer activityNeutrophil cytosol factor 1Homo sapiens (human)
superoxide-generating NAD(P)H oxidase activityNeutrophil cytosol factor 1Homo sapiens (human)
SH3 domain bindingNeutrophil cytosol factor 1Homo sapiens (human)
phosphatidylinositol bindingNeutrophil cytosol factor 1Homo sapiens (human)
phosphatidylinositol-3,4-bisphosphate bindingNeutrophil cytosol factor 1Homo sapiens (human)
superoxide-generating NADPH oxidase activator activityNeutrophil cytosol factor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
proteasome complex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
extracellular region26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
nucleoplasm26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
cytosol26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
secretory granule lumen26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
ficolin-1-rich granule lumen26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome regulatory particle, lid subcomplex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
proteasome accessory complex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
cytosolic proteasome complex26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
nucleus26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)
cytosolNeutrophil cytosol factor 1Homo sapiens (human)
plasma membraneNeutrophil cytosol factor 1Homo sapiens (human)
cytoplasmic side of plasma membraneNeutrophil cytosol factor 1Homo sapiens (human)
membraneNeutrophil cytosol factor 1Homo sapiens (human)
dendriteNeutrophil cytosol factor 1Homo sapiens (human)
phagolysosomeNeutrophil cytosol factor 1Homo sapiens (human)
NADPH oxidase complexNeutrophil cytosol factor 1Homo sapiens (human)
neuronal cell bodyNeutrophil cytosol factor 1Homo sapiens (human)
cytoplasmNeutrophil cytosol factor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID219087Association constant with ferriprotoporphyrin IX.2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Structure-function relationships in aminoquinolines: effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of beta-hematin formation, and antiplasmodial activity.
AID307626Solubility in water
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1582668Covalent inhibition of recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells interaction with Cy5-p22phox149-162 incubated for 10 mins by fluorescence polarization competition assay2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID1480589Inhibition of 26S proteasome regulatory subunit RPN11 deubiquitinating activity in human erythrocytes using Ub4-pepOG protein substrate preincubated for 1 hr followed by substrate addition measured after 80 mins by fluorescence polarization assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Discovery of an Inhibitor of the Proteasome Subunit Rpn11.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1582677Binding affinity to immobilized recombinant human His-tagged p47phox SH3A-B domain (151 to 285 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as maximal response by SPR assay relative to quinolin-2-amine2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1893771Inhibition of recombinant human QC using H-Gln-AMC hydrobromide as fluorogenic substrate incubated for 6 hrs by fluorometric microplate reader analysis2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID158544In vitro antiplasmodial activity against Plasmodium falciparum D102000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Structure-function relationships in aminoquinolines: effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of beta-hematin formation, and antiplasmodial activity.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID226297Inhibition of Beta-hematin (hemozoin) formation; No inhibition.2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Structure-function relationships in aminoquinolines: effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of beta-hematin formation, and antiplasmodial activity.
AID307625Partition coefficient, log P of the compound
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (206)

TimeframeStudies, This Drug (%)All Drugs %
pre-199044 (21.36)18.7374
1990's14 (6.80)18.2507
2000's40 (19.42)29.6817
2010's87 (42.23)24.3611
2020's21 (10.19)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.51 (24.57)
Research Supply Index5.40 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index61.43 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (3.27%)5.53%
Reviews22 (10.28%)6.00%
Case Studies3 (1.40%)4.05%
Observational0 (0.00%)0.25%
Other182 (85.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]